Comparison of fondaparinux XXXX and low molecular weight heparin in the treatment of @entity49 secondary to @entity281 .

@entity1 @entity2002 @entity548 @entity27408 @entity1372 @entity49 @entity1150 @entity281 @entity3459 @entity881
PURPOSE: To compare the effects and side-effects of @entity27408 and low molecular weight heparin in @entity1 with @entity49 accompanied with @entity281 . METHODS: Thirty-six @entity1 with post-traumatic infections in our hospital intensive care center were diagnosed with @entity49 from February 2012 to February 2013. These @entity1 were randomly divided into 2 groups. In group F (18 @entity1 ), the @entity1 were treated with fondaparinux @entity1372 , 2.5 mg, 1/d for 11 d. In group L (18 @entity1 ), the @entity1 were treated with low molecular weight heparin, 4100 U, 1/12 h for 11 d. The incidence of @entity1150 , @entity548 events and @entity881 ( @entity881 ) and mortality of two groups after anticoagulation therapy were analyzed. @entity2002 , D-dimer level and activity of antithrombin III were measured by the coagulation analyzer. RESULTS: The incidence of @entity1150 , @entity881 incidence and mortality were not significantly different between the two groups. The rate of @entity548 evens in group F was lower than group L (p < 0.05). Antithrombin III got an upward trend after anticoagulant therapy, in which it was higher in group F than in group L on the 5th d and 11th d (p<0.05). @entity2002 levels were gradually increased, and there was no significant difference between two groups (p>0.05). D-dimer was significantly decreased after anticoagulant therapy for 5 d (p<0.01), and there were significant differences between two groups on the 5th d and 7th d (p<0.05). It showed no significant difference on the 11th d (p>0.05). CONCLUSION: Fondaparinux @entity1372 and low molecular weight heparin can effectively improve @entity3459 in @entity1 with @entity281 . Compared with low molecular weight heparin, fondaparinux @entity1372 may reduce the risk of @entity548 events in @entity1 with @entity49 accompanied by @entity281 .
